Stay updated with breaking news from Exscientia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines * ... | January 7, 2022
Sanofi’s new alliance with artificial intelligence biotech Exscientia spans up to 15 small molecule drugs in cancer and immunology. If drugs from the partnership reach the market, Exscientia could earn as much as $5.2 billion in milestone payments.
Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers 54% of patients
Citi, acting through Citibank N.A., has been appointed by Exscientia plc ("Exscientia"), an AI-driven pharmatech company committed to designing and developing the best possible drugs in the fastest and
Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the